Photo

Photo detail

Urovant Sciences CEO Jim Robinson.

Stories this photo appears in:

Urovant Stumbles Ahead Of Commercial Launch

Irritable Bowel Treatment Results Fall Short

Irvine-based Urovant Sciences Ltd.'s flagship drug Vibegron missed endpoint in a phase 2a clinical trial for the abdominal pain treatment.

Tease photo